Nataliya Uboha, MD, PhD, has been selected to lead the Cancer Therapy Discovery and Development (CTD2) program at the University of Wisconsin Carbone Cancer Center.
As faculty leader for CTD2, formerly known as “Phase 1,” she will oversee UW Carbone’s ongoing efforts to launch first-in-human clinical trials, bringing novel cancer therapies to the patients who need them most.
“Dr. Uboha is recognized as an innovative and strategic leader, helping both in streamlined patient accrual as well as clinical trial activation,” said Lee Wilke, MD, associate director of clinical research at UW Carbone. “She will be a huge asset in this role as we continue to grow this program.”
Uboha is an assistant professor of medicine at the University of Wisconsin School of Medicine and Public Health. Her area of expertise is gastrointestinal cancers, with a particular emphasis on hepatobiliary and gastroesophageal cancers.
Her research focuses on the development of early phase and biomarker based clinical trials for patients with gastrointestinal malignancies. Uboha has significant clinical trial experience having served as a principal investigator on multiple investigator-initiated and industry sponsored studies and has led several early-phase clinical trials evaluating novel therapeutic approaches for patients with neuroendocrine tumors, esophageal cancers and pancreatic malignancies.
She co-directs the Wisconsin Oncology Network, a regional network that allows community health centers to enroll patients in select cancer clinical trials that are open at UW Carbone. She has also served as the faculty leader for UW Carbone’s Basket Disease Oriented Team (phase II disease agnostic), which has a specific focus on biomarker-based studies across disease types.